Related Experiment Videos
[Clinical evaluation of cefroxadine dry syrup in pediatric field (author's transl)]
Insights
Cefroxadine dry syrup demonstrated a 100% efficacy rate in treating pediatric scarlet fever and other infections. This cefroxadine formulation showed favorable pharmacokinetics and a good safety profile in children.
Area of Science:
- Pediatric Infectious Diseases
- Pharmacology
- Clinical Pharmacy
Background:
- Cefroxadine (CXD) is an antibiotic used for pediatric infections.
- Understanding its pharmacokinetic and clinical profile in children is crucial for effective treatment.
Purpose of the Study:
- To evaluate the clinical efficacy and safety of cefroxadine dry syrup in pediatric patients.
- To assess the serum levels and pharmacokinetic properties of cefroxadine in children.
Main Methods:
- Clinical evaluation of cefroxadine dry syrup in 33 children with scarlet fever and other infections.
- Serum level analysis after single oral administration.
- Assessment of clinical response and pathogen eradication over a 7-day treatment period.
Main Results:
- Cefroxadine dry syrup achieved a 100% clinical efficacy rate in treating scarlet fever, acute pharyngitis, tonsillitis, laryngotracheitis, and staphylococcal scalded skin syndrome.
- Peak serum levels were observed within 1 hour, with a half-life of approximately 1-1.2 hours.
- Group A Streptococcus was eradicated within 24 hours in scarlet fever cases. Only two cases of eosinophilia were noted as side effects.
Conclusions:
- Cefroxadine dry syrup is a highly effective and safe antibiotic for treating various pediatric infections.
- The drug exhibits favorable pharmacokinetic properties in children, supporting its clinical utility.
- The observed efficacy and safety profile suggest cefroxadine dry syrup as a valuable therapeutic option for pediatric infectious diseases.
Abstract:
Clinical evaluation was carried out on cefroxadine dry syrup (containing 100 mg of cefroxadine per 1 g) for child use, and the following results were obtained. 1. Serum levels: Peak serum levels at 1 hour after single administration of CXD 100 mg (9.1 mg/kg) to a 4-year old child (11kg) and 300 mg (12.8 mg/kg) to a 8-year old child (23.5 kg) were 20.32 microgram/ml and 18.75 microgram/ml, respectively. They declined to 0.78 microgram/ml and 0.88 microgram/ml respectively after 6 hours and to undetectable levels after 8 hours. Half-life was 1 hour and 1.2 hours, respectively. CXD has shown the same concentration pattern as CEX, except for the fact that serum levels were peaked after 30 minutes and not detectable after 6 hours. 2. Clinical responses: CXD was administered, for 7 days, to 33 children with scarlet fever in the dosage of greater than or equal 20 approximately less than 60 mg/kg/day (7 children in greater than or equal to 20 approximately 30 mg/kg/day, 21 in greater than or equal to 30 approximately less than 40 mg/kg/day and 5 in greater than or equal to 40 approximately less than 60 mg/kg/day). Clinical responses were excellent in 19 cases and good in 14 cases, with an efficacy rate of 100%. All strains of group A Streptococcus isolated from the pharynx of 22 children were eradicated within 24 hours. In 1 case each of acute pharyngitis, acute tonsillitis, acute laryngotracheitis and staphylococcal scalded skin syndrome, the dosage of greater than or equal to 30 approximately less than 45 mg/kg/day produced a 100% good clinical response and eliminated the causative pathogens. 3. Side effect: Only 2 cases of eosinophilia were observed in hematologic study as well as in hepatic and renal function tests before and after administration.